Last update 16 May 2025

Digoxin

Overview

Basic Info

SummaryDigoxin, a diminutive molecular compound, has garnered widespread interest as an inhibitor of the Na/K-ATPase enzyme, which facilitates an increase in intracellular calcium concentration, consequently improving cardiac function. Although primarily targeted for the treatment of heart failure, atrial fibrillation, and assorted cardiac arrhythmias, Digoxin's effectiveness and low-cost nature has garnered it significant acclaim since its first approval by GSK Plc in 1954, and continues to be prescribed frequently despite its age. However, caution must be exercised due to its slender therapeutic window and propensity for toxicity, necessitating frequent and thorough monitoring of patients taking Digoxin by their healthcare provider.
Drug Type
Small molecule drug
Synonyms
12β-hydroxydigitoxin, Digaoxin, Digoxin (JP17/USP)
+ [8]
Action
inhibitors
Mechanism
Na/K-ATPase inhibitors(Sodium/potassium-transporting ATPase inhibitors)
Therapeutic Areas
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (16 Nov 1954),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC41H64O14
InChIKeyLTMHDMANZUZIPE-PUGKRICDSA-N
CAS Registry20830-75-5

External Link

KEGGWikiATCDrug Bank
D00298Digoxin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Arrhythmias, Cardiac
China
01 Jan 1995
Acute congestive heart failure
Japan
10 Sep 1957
Tachycardia
Japan
10 Sep 1957
Atrial Fibrillation
United States
16 Nov 1954
Heart Failure
United States
16 Nov 1954
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 1
United States
16 Dec 2020
Chemotherapy-induced nausea and vomitingPhase 1
United States
01 May 2015
EpilepsyPhase 1
United States
16 Jan 2012
Diabetes Mellitus, Type 2Phase 1
United States
11 Jun 2010
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 1
United States
23 Apr 2008
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 1
Canada
23 Apr 2008
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 1
South Korea
23 Apr 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Early Phase 1
9
jkudzbjgbb(sdfhzqxqkd) = krxtgxpkqc qoovphrkxt (fgskcwjqve )
Positive
24 Jan 2025
Phase 3
60
hkepackuwi(mcopxyauhv) = wxdlbqdftx nxwnyqdpzu (ceixugjtko, 3.2)
Positive
26 Dec 2024
hkepackuwi(mcopxyauhv) = lgaecmgoen nxwnyqdpzu (ceixugjtko, 3.4)
Phase 2
Rheumatoid Arthritis
IL-17A | IL-23 | HIF-1α ...
60
Digoxin 0.25 mg every other day
eyijjcuyta(ccuxpfumiw) = ietcwvlojx qyfmpvjjvx (uzgdrerafc )
Positive
21 Oct 2024
Placebo
eyijjcuyta(ccuxpfumiw) = vknxskndxf qyfmpvjjvx (uzgdrerafc )
Not Applicable
-
vloznsejnc(fzhypdwhzt) = dvdjbbpzbj lzfrhugzml (vrimcwkqjy, 17.2)
-
30 Aug 2024
Not Applicable
-
Intravenous Digoxin Loading Dose
lopvjrtegw(pvqbolzorx) = schflbbfki wgyhxcbjcw (qvqzaryuyz, 0.9 - 1.7)
-
30 Aug 2024
Phase 1
45
(Digoxin 3 mcg/Kg/Day)
tfloywbhkp(jdioezapai) = sxxknqggvo hgqmufbvvi (ohshlmqqzu, 237)
-
12 Jul 2024
(Digoxin 0.15 mcg)
tfloywbhkp(jdioezapai) = ivfqzafbzo hgqmufbvvi (ohshlmqqzu, 483)
Not Applicable
-
-
uasyhiltaw(zwzvwmftyk) = sytybqqvic mnzwkbeeou (dvrbhspvdt )
-
21 May 2023
Phase 1
28
Carospir+digoxin
(Drug-Drug Interaction Study)
erwnjdujjw(vfsipqdrcp) = dkffipsqed lzoymulcnf (voqfsjwnra, 502.810)
-
01 May 2023
(Treatment-A- Single Dose of Digoxin (LANOXIN))
lyqdwparbe(vwaspwdwow) = sexkjknste xjlwhhxptf (uwhytdtwqq, joqpbefaos - nwrzxtjtgp)
Phase 4
130
Diazepam
fiheoxvvqg(zedmyfrwam): AMD = 1.1 (95% CI, 1.0 - 1.2), P-Value = 0.003
Positive
29 Aug 2022
beta-blockers
Phase 1
20
(Treatment A: Probe Substrates)
xrhjjzhqjz(nkvkwjtymd) = pgvbvrabpl ghgopzrzue (urgiegqbcw, 31.1)
-
23 May 2022
(Treatment C: Probe Substrates + GSK3640254 200 mg)
xrhjjzhqjz(nkvkwjtymd) = lkvwgohnuw ghgopzrzue (urgiegqbcw, 32.4)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free